152 related articles for article (PubMed ID: 15371985)
1. Effects of trimethoprim and rifampin on the pharmacokinetics of the cytochrome P450 2C8 substrate rosiglitazone.
Niemi M; Backman JT; Neuvonen PJ
Clin Pharmacol Ther; 2004 Sep; 76(3):239-49. PubMed ID: 15371985
[TBL] [Abstract][Full Text] [Related]
2. Effect of rifampin on the pharmacokinetics of rosiglitazone in healthy subjects.
Park JY; Kim KA; Kang MH; Kim SL; Shin JG
Clin Pharmacol Ther; 2004 Mar; 75(3):157-62. PubMed ID: 15001966
[TBL] [Abstract][Full Text] [Related]
3. Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics of pioglitazone.
Jaakkola T; Backman JT; Neuvonen M; Neuvonen PJ
Clin Pharmacol Ther; 2005 May; 77(5):404-14. PubMed ID: 15900286
[TBL] [Abstract][Full Text] [Related]
4. Trimethoprim and the CYP2C8*3 allele have opposite effects on the pharmacokinetics of pioglitazone.
Tornio A; Niemi M; Neuvonen PJ; Backman JT
Drug Metab Dispos; 2008 Jan; 36(1):73-80. PubMed ID: 17913794
[TBL] [Abstract][Full Text] [Related]
5. The CYP2C8 inhibitor trimethoprim increases the plasma concentrations of repaglinide in healthy subjects.
Niemi M; Kajosaari LI; Neuvonen M; Backman JT; Neuvonen PJ
Br J Clin Pharmacol; 2004 Apr; 57(4):441-7. PubMed ID: 15025742
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and pharmacodynamics of rosiglitazone in relation to CYP2C8 genotype.
Kirchheiner J; Thomas S; Bauer S; Tomalik-Scharte D; Hering U; Doroshyenko O; Jetter A; Stehle S; Tsahuridu M; Meineke I; Brockmöller J; Fuhr U
Clin Pharmacol Ther; 2006 Dec; 80(6):657-67. PubMed ID: 17178266
[TBL] [Abstract][Full Text] [Related]
7. The effect of rifampin on the pharmacokinetics of oral and intravenous ondansetron.
Villikka K; Kivistö KT; Neuvonen PJ
Clin Pharmacol Ther; 1999 Apr; 65(4):377-81. PubMed ID: 10223773
[TBL] [Abstract][Full Text] [Related]
8. Rifampin markedly decreases and gemfibrozil increases the plasma concentrations of atorvastatin and its metabolites.
Backman JT; Luurila H; Neuvonen M; Neuvonen PJ
Clin Pharmacol Ther; 2005 Aug; 78(2):154-67. PubMed ID: 16084850
[TBL] [Abstract][Full Text] [Related]
9. Effect of quercetin on the pharmacokinetics of rosiglitazone, a CYP2C8 substrate, in healthy subjects.
Kim KA; Park PW; Kim HK; Ha JM; Park JY
J Clin Pharmacol; 2005 Aug; 45(8):941-6. PubMed ID: 16027405
[TBL] [Abstract][Full Text] [Related]
10. Effect of ketoconazole on the pharmacokinetics of rosiglitazone in healthy subjects.
Park JY; Kim KA; Shin JG; Lee KY
Br J Clin Pharmacol; 2004 Oct; 58(4):397-402. PubMed ID: 15373932
[TBL] [Abstract][Full Text] [Related]
11. Effect of multiple doses of montelukast on the pharmacokinetics of rosiglitazone, a CYP2C8 substrate, in humans.
Kim KA; Park PW; Kim KR; Park JY
Br J Clin Pharmacol; 2007 Mar; 63(3):339-45. PubMed ID: 16981900
[TBL] [Abstract][Full Text] [Related]
12. Effect of rifampicin on the pharmacokinetics of pioglitazone.
Jaakkola T; Backman JT; Neuvonen M; Laitila J; Neuvonen PJ
Br J Clin Pharmacol; 2006 Jan; 61(1):70-8. PubMed ID: 16390353
[TBL] [Abstract][Full Text] [Related]
13. The effect of trimethoprim on CYP2C8 mediated rosiglitazone metabolism in human liver microsomes and healthy subjects.
Hruska MW; Amico JA; Langaee TY; Ferrell RE; Fitzgerald SM; Frye RF
Br J Clin Pharmacol; 2005 Jan; 59(1):70-9. PubMed ID: 15606443
[TBL] [Abstract][Full Text] [Related]
14. Rifampin reduces plasma concentrations and effects of zolpidem.
Villikka K; Kivistö KT; Luurila H; Neuvonen PJ
Clin Pharmacol Ther; 1997 Dec; 62(6):629-34. PubMed ID: 9433391
[TBL] [Abstract][Full Text] [Related]
15. Rifampin greatly reduces plasma simvastatin and simvastatin acid concentrations.
Kyrklund C; Backman JT; Kivistö KT; Neuvonen M; Laitila J; Neuvonen PJ
Clin Pharmacol Ther; 2000 Dec; 68(6):592-7. PubMed ID: 11180018
[TBL] [Abstract][Full Text] [Related]
16. The effects of febuxostat on the pharmacokinetic parameters of rosiglitazone, a CYP2C8 substrate.
Naik H; Wu JT; Palmer R; McLean L
Br J Clin Pharmacol; 2012 Aug; 74(2):327-35. PubMed ID: 22242967
[TBL] [Abstract][Full Text] [Related]
17. Gemfibrozil markedly increases the plasma concentrations of montelukast: a previously unrecognized role for CYP2C8 in the metabolism of montelukast.
Karonen T; Filppula A; Laitila J; Niemi M; Neuvonen PJ; Backman JT
Clin Pharmacol Ther; 2010 Aug; 88(2):223-30. PubMed ID: 20592724
[TBL] [Abstract][Full Text] [Related]
18. The effects of human CYP2C8 genotype and fluvoxamine on the pharmacokinetics of rosiglitazone in healthy subjects.
Pedersen RS; Damkier P; Brosen K
Br J Clin Pharmacol; 2006 Dec; 62(6):682-9. PubMed ID: 16856883
[TBL] [Abstract][Full Text] [Related]
19. Effect of rifampin on the pharmacokinetics and pharmacodynamics of gliclazide.
Park JY; Kim KA; Park PW; Park CW; Shin JG
Clin Pharmacol Ther; 2003 Oct; 74(4):334-40. PubMed ID: 14534520
[TBL] [Abstract][Full Text] [Related]
20. Effects of fluconazole and fluvoxamine on the pharmacokinetics and pharmacodynamics of glimepiride.
Niemi M; Backman JT; Neuvonen M; Laitila J; Neuvonen PJ; Kivistö KT
Clin Pharmacol Ther; 2001 Apr; 69(4):194-200. PubMed ID: 11309547
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
